News
Thu, 02 Jan 2020 08:30:00 -0500
Thu, 02 Jan 2020 08:30:00 -0500
PLAINSBORO, N.J., January 2, 2020 /PRNewswire/ – Today, Novo Nordisk launched the My$99Insulin Program, follow-on brands of insulins, and an Immediate Supply option, expanding its insulin affordability offerings to help people with diabetes who need alternative solutions. These options, along with information on the existing patient assistance program, copay cards, and where to find $25/vial human insulin, are now available online at NovoCare.com or by calling 1.844.NOVO4ME (1.844.668.6463).
“We know some people still struggle to afford their insulin and we want to help. We’ve talked to people, including those who have been critical of us, and it’s clear there is no one solution that will work for everyone and people need options,” said Doug Langa, executive vice president, North America Operations and president of Novo Nordisk Inc. “That’s why today, we have made available additional options recognizing the different situations that make insulin unaffordable or inaccessible. With these programs, in conjunction with NNI’s investment in rebates to ensure our medicines are on formularies, we are continuing to take action to help people with diabetes afford their insulin as we work toward much needed longer-term change.”
Expanded affordability options now available
|
Product Name |
WAC/Pkg |
|
Insulin Aspart (FOB) vial |
$144.68 |
|
Insulin Aspart PenFill® cartridge (FOB) - 5x3mL |
$268.73 |
|
Insulin Aspart FlexPen® (FOB) - 5x3mL |
$279.41 |
|
Insulin Aspart Mix 70/30 (FOB) 10mL vial |
$150.06 |
|
Insulin Aspart Mix 70/30 FlexPen® (FOB) - 5x3mL |
$279.41 |
“We have heard that sometimes accessing our programs and medicines can be complicated and we want to change that. We have enhanced our one-stop-shop affordability hub, NovoCare®, based on community feedback. And, we are doing more to make people aware of all the programs and options across Novo Nordisk companies that may benefit them,” said Langa. “We’ll continue working within the system and find additional short- and long-term actions we can take that will directly benefit people with diabetes. Most importantly, we encourage anyone who needs help to call us or visit NovoCare®. A lot has changed and we want to connect people with affordability challenges with a solution.”
NovoCare.com
NovoCare.com is the go-to resource for patients and healthcare professionals for all of Novo Nordisk’s support programs. You just have to provide some basic information – what insulin is used, and healthcare coverage – at NovoCare.com to find options that fit your situation, such as:
Affordability options already in place
The new options build upon programs Novo Nordisk already offers including:
To learn more about these offerings and to view full eligibility requirements, visit NovoCare.com or call 1.844.NOVO4ME (1.844.668.6463).
We continue our commitment to affordability and access
We’ll continue to work towards longer-term reform that makes it easier for people who need our medicines to get them. For instance, we support the recent IRS ruling that classifies diabetes medications as preventive care. We believe this has the potential to help a significant number of people with diabetes from an affordability perspective. Novo Nordisk employees who interact with decision makers are actively requesting that insurance plans adopt this rule.
About Novo Nordisk:
Novo Nordisk, a global healthcare company based in Denmark, has been committed to discovering and developing innovative medicines to help people living with diabetes lead longer, healthier lives for 95 years. This heritage has given us experience and capabilities that also enable us to help people defeat other serious diseases including obesity, hemophilia and growth disorders. We remain steadfast in our conviction that the formula for success is to stay focused, think long term and do business in a financially, socially and environmentally responsible way. In the US, Novo Nordisk employs nearly 6,000 people across affiliate companies and production and research facilities in six states.
About Novo Nordisk Inc. (NNI):
NNI is a US affiliate of Novo Nordisk. The company is based in Plainsboro, NJ and is responsible for commercialization of Novo Nordisk brands in the US and management of clinical trials in the US. For more information, visit novonordisk.us, Facebook, Instagram and Twitter.
About Novo Nordisk Pharma, Inc. (NNPI):
Novo Nordisk Pharma, Inc. (NNPI) is a newly established Novo Nordisk A/S US company that is also based in Plainsboro, NJ. The company was formed in March 2019 to bring follow-on brands of Novo Nordisk insulin products at a reduced list price for people facing affordability challenges.